XNASIOBT
Market cap58mUSD
Dec 23, Last price
0.89USD
1D
15.38%
1Q
-14.46%
IPO
-93.23%
Name
IO Biotech Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-86m
L+20.47%
CFO
-72m
L+20.10%
Profile
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 92,199 | 71,964 | 41,234 | ||
Unusual Expense (Income) | |||||
NOPBT | (92,199) | (71,964) | (41,234) | ||
NOPBT Margin | |||||
Operating Taxes | 852 | 1,273 | 68 | ||
Tax Rate | |||||
NOPAT | (93,051) | (73,237) | (41,302) | ||
Net income | (86,083) 20.47% | (71,458) 5.27% | (67,879) 462.47% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 75,058 | 115,115 | |||
BB yield | -91.70% | -62.42% | |||
| Debt | |||||
Debt current | 1,310 | 515 | |||
Long-term debt | 4,333 | 5,065 | |||
Deferred revenue | |||||
Other long-term liabilities | 59 | ||||
Net debt | (137,550) | (137,278) | (211,799) | ||
| Cash flow | |||||
Cash from operating activities | (71,737) | (59,729) | (40,646) | ||
CAPEX | (323) | (690) | (153) | ||
Cash from investing activities | (323) | (690) | (153) | ||
Cash from financing activities | 71,860 | 252,951 | |||
FCF | (92,923) | (76,316) | (41,457) | ||
| Balance | |||||
Cash | 143,193 | 142,590 | 211,531 | ||
Long term investments | 268 | 268 | |||
Excess cash | 143,193 | 142,858 | 211,799 | ||
Stockholders' equity | (273,425) | (187,851) | (107,741) | ||
Invested Capital | 409,736 | 329,495 | 319,724 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 43,540 | 28,815 | 28,815 | ||
Price | 1.88 -18.26% | 2.30 -64.06% | 6.40 | ||
Market cap | 81,855 23.51% | 66,275 -64.06% | 184,418 | ||
EV | (55,695) | (71,003) | (27,381) | ||
EBITDA | (91,443) | (71,424) | (41,232) | ||
EV/EBITDA | 0.61 | 0.99 | 0.66 | ||
Interest | 302 | 361 | |||
Interest/NOPBT | |||||